Medicamen Biotech

Medicamen Biotech EBIT Margin

The EBIT Margin (Operating Margin) of Medicamen Biotech (MEDICAMEQ.NS) as of Oct 19, 2026 is 6.25 %. In the previous year, EBIT Margin (Operating Margin) was 8.02 % — a change of -22.02% (lower).

EBIT Margin

6.25 %

YoY

-22.02%

Last updated:

EBIT Margin (Operating Margin) of Medicamen Biotech is 2026 6.25 % . EBIT Margin (Operating Margin) of Medicamen Biotech was 2025 8.02 % . It decreases by -22.02% lower compared to the previous year.

Medicamen Biotech's operating (EBIT) margin stands at 6.3%, down from 16.2% several years earlier.

The Medicamen Biotech EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2019
15.06 INR
Jan 1, 2020
15.07 INR
Jan 1, 2021
15.52 INR
Jan 1, 2022
16.20 INR
Jan 1, 2023
12.95 INR
Jan 1, 2024
28.82 INR
Jan 1, 2025
8.02 INR
Jan 1, 2026
6.25 INR
The Medicamen Biotech EBIT Margin history
YEAREBIT MarginYoY
6.25 %-22.02%
8.02 %-72.18%
28.82 %+122.54%
12.95 %-20.06%
16.20 %+4.39%
15.52 %+3.01%
15.07 %+0.08%
15.06 %+13.92%
13.22 %+71.49%
7.71 %+628.49%
1.06 %+599.99%
0.15 %-38.06%
0.24 %-420.27%
-0.08 %+1,068.48%
-0.01 %-118.61%
0.04 %-39.73%
0.06 %+186.12%
0.02 %-16.72%
0.02 %-24.07%
0.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medicamen Biotech Stock analysis

What does Medicamen Biotech do? Medicamen Biotech Ltd, based in New Delhi, India, operates in the Health Care sector, specifically within Pharmaceuticals. The company manufactures and markets diverse pharmaceutical formulations, including oral solids, liquids, ointments, and injectables for both non-oncology and oncology treatments. It focuses on oncology therapeutics, cardiology, central nervous system disorders, diabetology, and pain management. With 388 employees, Medicamen Biotech produces a range of products such as tablets, capsules, syrups, and specialized oncology drugs like Abiraterone acetate and Imatinib mesylate. Medicamen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medicamen Biotech stock

EBIT Margin (Operating Margin) of Medicamen Biotech is 6.25 % in 2026.

EBIT Margin (Operating Margin) of Medicamen Biotech changed from 8.02 % to 6.25 %, representing a -22.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Medicamen Biotech since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Medicamen Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Medicamen Biotech

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Medicamen Biotech